Select Page

Clinical Evidence

COMBAT BRS HIVEC® Treatment

Download Brochure

EN / ES Please contact us for further languages
COMBAT Medical is committed to investing in research and development, clinical trials and real world evidence based studies. Demonstrating the effectiveness of Combat’s patented technology and creating a solid foundation for its use.

Please click a category below to view the abstracts

HIVEC in High Risk NMIBC
BCG vs Chemohyperthermia with Mitomycin C for High-Risk Non-Muscle Invasive Bladder Carcinoma: Preliminary Results of HIVEC-HR Randomised Clinical Trial. 2019 and 2020
ABSTRACT: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000823.01 PDF: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000000823.01
Chemohyperthermia with Mitomycin C (MMC) and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC): A New Alternative? ABSTRACT: https://www.auajournals.org/doi/10.1016/j.juro.2018.02.2757 PDF: https://www.auajournals.org/doi/pdf/10.1016/j.juro.2018.02.2757
Chemohyperthermia with Mitomycin C and COMBAT System in High Risk Non-Muscle Invasive Bladder Cancer Patients: Initial Experience in a Single Centre https://abstracts.mirrorsmed.org/abstracts/chemohyperthermia-mitomycin-c-and-combat-system-high-risk-non-muscle-invasive-bladder
HIVEC in BCG Failure & BCG Unresponsive
Intravesical Chemohyperthermia (HIVEC) in BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients: Oncological Outcomes of a Multi-Centre European Registry EAU Resource Centre | EAU20V (uroweb.org) (need to login in order to view) Or https://www.researchgate.net/publication/343009316_Intravesical_chemohyperthermia_HIVEC-E_in_BCG_unresponsive_non-muscle_invasive_bladder_cancer_patients_Oncological_outcomes_of_a_multi-centre_European_registry (need to download full text PDF) Hyperthermic Intravesical Chemotherapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients Abstract https://www.auajournals.org/doi/full/10.1016/j.juro.2018.02.3007 & PDF https://www.auajournals.org/doi/pdf/10.1016/j.juro.2018.02.3007 Heat Targeted Drug Delivery (COMBAT) in Superficial TCC: First Midterm Results in a Cohort of High-Risk Patients Scheduled for Cystectomy https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.442
HIVEC in Neo-Adjuvant Setting
Chemo-Resection with Hyperthermic Intravesical Instillation (HIVEC-R) Vs Standard Treatment in Patients With Intermediate-High Risk Nmibc: Comparative, Prospective, Randomized, Controled Study of Efficacy and Tolerability: Preliminary Results
Abstract MP73-06 CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH INTERMEDIATE-HIGH RISK NMIBC: COMPARATIVE, PROSPECTIVE, RANDOMIZED, CONTROLED STUDY OF EFFICACY AND TOLERABILITY: PRELIMINARY RESULTS | Journal of Urology (auajournals.org) & PDF MP73-06 CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH INTERMEDIATE-HIGH RISK NMIBC: COMPARATIVE, PROSPECTIVE, RANDOMIZED, CONTROLED STUDY OF EFFICACY AND TOLERABILITY: PRELIMINARY RESULTS (auajournals.org)
The Reduction of the Neutrophil / Lymphocyte Ratio (NLR) is Associated with a Complete Response and Disease-Free Survival in Patients with Non-Muscle Invasive Bladder Cancer Treated with Intravesical Neoadjuvant Chemohyperthermia
Poster presentation at https://www.aeu.es/aplicaciones/presentaciones/guo2019.aspx#
HIVEC in Perioperative
Prospective Randomised Clinical Trial of Chemo-hyperthermia with Mitomycin-C Prior to Transurethral Resection of the Bladder and its Relationship with the Rate of Early Recurrence in Non-Muscle Invasive Bladder Cancer: Intermediate Analysis
Abstract: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000922.12 PDF: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000000922.12
HIVEC in High Risk in a Sequential Therapy Regime with BCG
One Year Follow up Results After Sequential Intravesical Bacillus Calmette-Guérin and Device Assisted Chemo-Hyperthermia (Mitomycin C Delivered by The COMBAT BRS System) for High Risk Non-Muscle Invasive Bladder Cancer Patients… A Bacillus Calmette-Guérin Sparing Strategy https://university.auanet.org/abstract_detail.cfm?id=PD19-07&meetingID=17BOS
HIVEC in Intermediate - High Risk NMIBC
HIVEC® in Intermediate – High Risk Non-Muscle Invasive Bladder Cancer https://www.tandfonline.com/doi/full/10.3109/02656736.2016.1142618
Safety & Tolerability & Quality of Life
Safety and Tolerability Analysis of Hyperthermic Intravesical Mitomycin to Mitomycin alone in HIVEC I and HIVEC II: An Interim Analysis of 307 Patients https://www.researchgate.net/publication/315589552_Safety_and_tolerability_analysis_of_hyperthermic_intravesical_mitomycin_to_mitomycin_alone_in_HIVEC_I_and_HIVEC_II_An_interim_analysis_of_307_patients
Quality of Life (QoL), Non Muscle Invasive Bladder Cancer (NMIBC) and Endovesical Treatments: Installation Matters https://abstracts.mirrorsmed.org/abstracts/quality-life-qol-non-muscle-invasive-bladder-cancer-nmibc-and-endovesical-treatments
Hyperthermia Mode of Action
To Register for Clinical Updates

12 + 10 =

English EN Spanish ES